The formulation problem: making adult drugs work for small bodies
A tablet that suits a 70kg adult is often useless for a toddler. Getting the dose, the taste and the ingredients right is a development programme in its own right.
In brief
Why adult medicines often fail children: dose flexibility, taste and excipient safety, and why paediatric formulation belongs early in drug development.
- A licensed molecule is only half a paediatric medicine; the dosage form is the other half.
- Dose flexibility, palatability and excipient safety are the three recurring problems.
- Regulators expect formulation work to be planned in the paediatric investigation plan, not improvised later.
An approved molecule is only half of a paediatric medicine. The other half is a dosage form a child can actually take, at a dose that can be measured accurately across a weight range that may run from under a kilogram in a premature baby to adult size in a teenager.
Dose flexibility
Oral liquids have long been the default because the volume can be adjusted. They bring their own problems: limited stability, the need for preservatives, bulky packaging, and dosing errors when carers measure with household spoons rather than oral syringes.
Mini-tablets, typically two to four millimetres across, have become a credible alternative. A clinician can scale a dose by count, and studies have found that even young children can swallow them. Orodispersible tablets and films, which dissolve in the mouth, are another option for children who cannot swallow solids.
Taste and swallowability
Bitter active ingredients are a leading cause of refused or spat-out doses. Taste-masking through coatings, sweeteners or flavours adds cost and complexity, and regulators expect evidence that the result is acceptable to the target age group. A medicine that children will not take is not an effective medicine, whatever the trial data say.
Excipients
Ingredients that are unremarkable in adults can be a concern in neonates and infants, whose ability to metabolise and excrete them is still developing. Ethanol, propylene glycol, benzyl alcohol and some preservatives all attract scrutiny in paediatric formulations, and developers increasingly design them out from the start.
Why it belongs early in development
In the EU and UK, formulation is part of the agreed paediatric investigation plan, and an age-appropriate form is often a condition of compliance. Leaving it until after adult approval is a common reason paediatric programmes run late. The companies that handle it best treat the paediatric formulation as a parallel workstream from the moment a drug looks likely to reach children.
